Indaptus Therapeutics initiates Phase 1 study of Decoy20
Indaptus Therapeutics (INDP) announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion ...
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint ...
About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...